Related references
Note: Only part of the references are listed.Malondialdehyde, lipoprotein-a, lipoprotein ratios, comprehensive lipid tetrad index and atherogenic index as surrogate markers for cardiovascular disease in patients with psoriasis: a case-control study
Dhaarna Wadhwa et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2019)
Associations between paraoxonase 1 (PON1) polymorphisms and susceptibility and PON1 activity in rheumatoid arthritis patients, and comparison of PON1 activity in patients and controls: a meta-analysis
Sang-Cheol Bae et al.
CLINICAL RHEUMATOLOGY (2019)
Correlation of High-Density Lipoprotein-Associated Paraoxonase 1 Activity With Systemic Inflammation, Disease Activity, and Cardiovascular Risk Factors in Psoriatic Disease
M. Elaine Husni et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Associations of the PON1 rs662 polymorphism with circulating oxidized low-density lipoprotein and lipid levels: a systematic review and meta-analysis
Zhi Luo et al.
LIPIDS IN HEALTH AND DISEASE (2018)
Genotype and phenotype of salt-stimulated paraoxonase 1 (PON1) is associated with atherogenic indices in type 2 diabetes
Durdi Qujeq et al.
JOURNAL OF DIABETES AND METABOLIC DISORDERS (2018)
High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus
Krisztina Gaal et al.
LIPIDS IN HEALTH AND DISEASE (2016)
Prevalence of cardiovascular disease risk factors, and metabolic syndrome and its components in patients with psoriasis aged 30 to 49 years
Agnieszka B. Owczarczyk-Saczonek et al.
POSTEPY DERMATOLOGII I ALERGOLOGII (2015)
Association between PON1 rs662 polymorphism and coronary artery disease
T. Liu et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2014)
Quantifying cardiovascular disease risk factors in patients with psoriasis: a meta-analysis
I. M. Miller et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Psoriasis and risk of cardiovascular disease: A meta-analysis of cohort studies
Wan-Jie Gu et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Genetic Polymorphisms of Paraoxonase 1 and Susceptibility to Atherogenesis
Ivana Grubisa et al.
SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO (2013)
Clinical and Genetic Association of Serum Paraoxonase and Arylesterase Activities With Cardiovascular Risk
W. H. Wilson Tang et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1
G. Ferretti et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis
M. Asefi et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Prevalence of Metabolic Syndrome in Patients with Psoriasis: A Population-Based Study in the United Kingdom
Sinead M. Langan et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Paraoxonase 1 192 and 55 polymorphisms in osteosarcoma
Arzu Ergen et al.
MOLECULAR BIOLOGY REPORTS (2011)
Serum lipid profile paraoxonase and arylesterase activities in psoriasis
Aysun Toker et al.
CELL BIOCHEMISTRY AND FUNCTION (2009)
Validation of PON1 enzyme activity assays for longitudinal studies
Karen Huen et al.
CLINICA CHIMICA ACTA (2009)
The roles of PON1 and PON2 in cardiovascular disease and innate immunity
Diana M. Shih et al.
CURRENT OPINION IN LIPIDOLOGY (2009)
Oxidative stress in the pathogenesis of psoriasis
Qiang Zhou et al.
FREE RADICAL BIOLOGY AND MEDICINE (2009)
Genetic admixture, relatedness, and structure patterns among Mexican populations revealed by the Y-chromosome
H. Rangel-Villalobos et al.
AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY (2008)
Paraoxonase 1 Gene Polymorphisms and Enzyme Activities in Diabetes Mellitus
M. Flekac et al.
PHYSIOLOGICAL RESEARCH (2008)
Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients
Nilgun Solak Tekin et al.
MEDIATORS OF INFLAMMATION (2007)
Psoriasis is associated with lipid abnormalities at the onset of skin disease
L Mallbris et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Concerning the significance of paraoxonase-1 and SR-B1 genes in atherosclerosis
F Rodríguez-Esparragón et al.
REVISTA ESPANOLA DE CARDIOLOGIA (2006)
Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis
G Baskol et al.
CLINICAL BIOCHEMISTRY (2005)
Paraoxonase 1 (PON1) is present in postprandial chylomicrons
B Fuhrman et al.
ATHEROSCLEROSIS (2005)
Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells
S Deakin et al.
ATHEROSCLEROSIS (2005)
SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci
YY Shi et al.
CELL RESEARCH (2005)
Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development
M Aviram et al.
FREE RADICAL BIOLOGY AND MEDICINE (2004)
Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis
BV Kural et al.
CLINICA CHIMICA ACTA (2003)
Paraoxonase status in coronary heart disease - Are activity and concentration more important than genotype?
B Mackness et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2001)
Advances in immunology - Autoimmune diseases
A Davidson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype
GP Jarvik et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions - PON1 esterase and peroxidase-like activities
M Aviram et al.
CIRCULATION (2000)
Calcium-dependent human serum homocysteine thiolactone hydrolase -: A protective mechanism against protein N-homocysteinylation
H Jakubowski
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
